Clinical Resources: Buprenorphine in Borderline Personality Disorder
Primary Care Materials
This page hosts practical resources for clinicians and patients exploring the potential role of buprenorphine in Borderline Personality Disorder (BPD), particularly in cases marked by severe interpersonal dysregulation, affective instability, and self-injurious behavior.
These materials are educational and mechanism-focused. They are not formal treatment guidelines and do not replace clinical judgment.
Primary Care Guide
These guides are written for primary care clinicians and other prescribers who are comfortable with buprenorphine in other contexts (e.g., pain or OUD) but have not considered its potential role in affective and interpersonal dysregulation.
Status
These guides are shared to invite thoughtful feedback from clinicians, researchers, and people with lived experience. They are working documents and will be revised as new evidence and clinical insight develops.
Changelog
Document version history
PCP Guide
| Date | Version | Changes |
|---|---|---|
| March 25, 2026 | v0.15 | Added authorship and provenance disclosure to opening section. |
| April 1, 2026 | v0.16 | Added citations throughout. New supporting sentences added for Prossin et al. (2010) on PET neuroimaging evidence for μ-opioid receptor availability in BPD, New and Stanley (2010) on the endogenous opioid deficit synthesis, Gescher et al. (2024) on trauma-linked OPRK1 methylation changes, and Khalili et al. (2019) in the bipolar spectrum section. |
| April 4, 2026 | v0.17 | Refined naltrexone contraindication language throughout: replaced "absolutely contraindicated" with "contraindicated in primary care settings," scoped the contraindication explicitly to milligram-dosed formulations, and added a carve-out acknowledging experimental concurrent ultra-low-dose naltrexone (ULDN, <10 mcg) use in pain management literature while noting it falls outside routine primary care protocols. Updated PDMP section to clarify that only concurrent milligram-dosed naltrexone is contraindicated. Added citation for Toljan and Vrooman (2018) on LDN to support the ULDN concurrent use statement. Added new Section 6.3 describing the Norelli et al. (2013) case series on buprenorphine for treatment-refractory NSSI, with discussion of aggregate outcome data, prior naltrexone failure across cases, and tolerability considerations. Added Norelli et al. (2013) to Section 13 evidence summary. Added Bershad et al. (2015) as a new evidence thread in Section 13 on buprenorphine's attenuation of psychosocial stress responses in a controlled human experimental paradigm. |
| April 8, 2026 | v0.18 | Added citations throughout. In Section 1, refined prevalence language to distinguish point prevalence from lifetime prevalence estimates and disaggregated clinical setting prevalence figures by care context (primary care, psychiatric outpatient, psychiatric inpatient); added citations for Lenzenweger et al. (2007), Grant et al. (2008), Gross et al. (2002), and Lieb et al. (2004). Added Riihimäki et al. (2014) on BPD prevalence among primary care depressive patients. Added Paris and Zweig-Frank (2001), Temes et al. (2019), and Wu et al. (2022) to support suicide mortality figures. Added Bender et al. (2001) on healthcare utilization. Added Sansone and Sansone (2012) on chronic pain comorbidity. Added Eisenberger et al. (2003) on the neural overlap of social and physical pain. Added Pitman et al. (1990) on naloxone-reversible stress-induced analgesia in PTSD. Added Lutz and Kieffer (2013) on opioid receptor roles in mood disorders. Added Lutfy and Cowan (2004) on buprenorphine pharmacology. Added Simeon and Knutelska (2005) on naltrexone in depersonalization disorder. Added Pergolizzi et al. (2010) on buprenorphine pharmacological profile. Added Stoffers-Winterling et al. (2022) on pharmacological interventions for BPD. Added Strain et al. (2004) on naloxone sublingual bioavailability. Added Posner et al. (2011) on the C-SSRS. Added McEwen (2017) on neuroplastic effects of chronic stress. Added ACOG Committee Opinion (2017) on opioid use in pregnancy. Added Linehan (1993) on the biosocial theory of BPD. Added Roth et al. (1996) on naltrexone for repetitive self-injurious behavior. Added Younger et al. (2014) on low-dose naltrexone mechanism. Added FDA Suboxone prescribing information and FDA benzodiazepine drug class boxed warning (2020) as regulatory references. |
| May 11, 2026 | v0.19 | Removed naloxone-as-deterrent framing; buprenorphine/naloxone now presented as an availability-based formulation option rather than a clinical upgrade (Sections 6.2, 7.2). Removed ongoing urine drug screening from monitoring protocol; retained baseline screening for precipitated withdrawal risk; reframed PDMP review around drug interaction safety (Section 7.3). Removed "misuse or diversion" language from continued prescribing conditions and discontinuation criteria (Section 7.3). Revised addiction medicine referral language (Section 10) and addiction risk FAQ (Section 12) accordingly. Added new FAQ on opioid-induced hyperalgesia, discussing buprenorphine's antihyperalgesic profile and kappa-antagonism mechanism. Added Koppert et al. (2005) on differential analgesic and antihyperalgesic profiles of buprenorphine in a human pain model. |
| May 14, 2026 | v0.20 | Expanded discussion of buprenorphine/naloxone formulation tolerability. In Section 6.2, qualified the statement that sublingual naloxone does not meaningfully alter clinical effect — noting it is detectable in nearly all patients with inter-individual variability and can contribute to adverse, occasionally treatment-limiting side effects in a minority. Added a bullet to Section 6.3 on Norelli et al. (2013) Patient 1, who received a buprenorphine/naltrexone combination reduced from 2/0.5 mg to 1/0.25 mg because of dizziness, with discussion of why naltrexone rather than naloxone is the more pharmacologically coherent co-formulated antagonist. Expanded Section 7.2 formulation guidance with the Braun et al. (2024) case of post-administration nausea and anxiety that resolved on transition to the buprenorphine monoproduct, and added reasoning that monotherapy is the safer default absent a specific indication for the combination product. Added Braun et al. (2024) on buprenorphine/naloxone formulation tolerability and Blazes and Morrow (2020) on the limited evidence that naloxone deters injection misuse. |
| May 16, 2026 | v0.21 | Added buccal buprenorphine film (Belbuca) to Section 7.2 as a commercially available option for low-dose initiation, expanding the below-2-mg practicalities subsection from two options to three and noting that its chronic pain indication can support insurance coverage where pain is comorbid. Expanded the Section 7.2 transdermal formulation note to identify branded Butrans and generic transdermal patches, their strength range, and the chronic pain indication that can likewise support coverage, with a caution that the lowest patch strength sits at the upper end of the low-dose range and may exceed the tolerance of highly sensitive patients. Added a baseline assessment item to Section 7.3 on naloxone rescue and overdose education, recommending take-home naloxone and overdose counseling, particularly where benzodiazepines or other CNS depressants are co-prescribed. Revised the sample patient script in Section 11, softening the description of the endogenous opioid mechanism to match the hypothesized framing used elsewhere in the document and adding discussion of physical dependence and gradual discontinuation, the possible attenuation of opioid analgesia, the need to disclose opioid antagonist use before initiation, and the time-limited nature of the trial. Revised the perioperative pain management answer in Section 12 to remove a claim of a rapid, well-tolerated taper that was inconsistent with Section 7.3, reframing perioperative buprenorphine management as an evolving area best decided with the surgical and anesthesia team. |
Quick Reference
| Date | Version | Changes |
|---|---|---|
| March 25, 2026 | v0.2 | Added authorship and provenance disclosure to footer. |
Guidance Notes
A case series (Norelli et al.) reported clinical use of buprenorphine/naltrexone combination products at doses of 2/0.5 mg and 1/0.25 mg in this context — naltrexone, not naloxone, which has negligible oral bioavailability and is used in standard sublingual formulations. As of v0.20, the PCP guide (Section 6.3) discusses this report, including why naltrexone rather than naloxone is the more pharmacologically coherent co-formulated antagonist and the dizziness that prompted a dose reduction in the patient who received it. The pharmacodynamic implications of the naltrexone component at these doses are still not fully characterized, and this remains an active area of attention. This note is retained for clinicians who may encounter or consider combination formulations.
If you have relevant clinical experience or insight into this combination, please get in touch.
Contact
For questions, feedback, or discussion:
contact@bpd.fyi